➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,169,780

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,169,780 protect, and when does it expire?

Patent 7,169,780 protects ISENTRESS, DUTREBIS, and ISENTRESS HD, and is included in four NDAs.

Protection for ISENTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in thirty-four countries.

Summary for Patent: 7,169,780
Title:N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Abstract:N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described ##STR00001##
Inventor(s): Crescenzi; Benedetta (Rome, IT), Gardelli; Cristina (Ariccia, IT), Muraglia; Ester (Rome, IT), Orvieto; Federica (Rome, IT), Pace; Paola (Rome, IT), Pescatore; Giovanna (Cosenza, IT), Petrocchi; Alessia (Rome, IT), Poma; Marco (Grosseto, IT), Rowley; Michael (Axa, IT), Scarpelli; Rita (Rome, IT), Summa; Vincenzo (Velletri, IT), Nizi; Emanuela (Siena, IT)
Assignee: Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (Pomezia, IT)
Application Number:10/493,280
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,169,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Merck Sharp Dohme ISENTRESS raltegravir potassium TABLET, CHEWABLE;ORAL 203045-001 Dec 21, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Merck Sharp Dohme ISENTRESS raltegravir potassium TABLET, CHEWABLE;ORAL 203045-002 Dec 21, 2011 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,169,780

PCT Information
PCT FiledOctober 21, 2002PCT Application Number:PCT/GB02/04753
PCT Publication Date:May 01, 2003PCT Publication Number: WO03/035077

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.